Ketim Technologies Closes Oversubscribed $1.2M Pre-Seed Round to Accelerate Predictive PPD Blood Test

Brisbane, Australia – October 18, 2025 – Ketim Technologies is proud to announce the successful oversubscribed close of its pre-seed investment round, raising a total of $1.2 million, including $725,000 from angel investors and non-dilutive funding support.

The round was oversubscribed by more than $200,000 and backed entirely by angel investors led by AngelLoop, marking a significant vote of confidence in Ketim’s mission to develop the world’s first predictive protein blood test for postpartum depression.

This funding will accelerate commercialisation of Ketim’s Multi-Protein Risk Score (MPRS) Postpartum Depression Test, with the company targeting market entry by 2027 in partnership with a global diagnostics company.

“I started with a mission. Then it became a necessity,” said Dr. Clarissa Yates, Founder and CEO of Ketim Technologies. “Having personally experienced postpartum depression, I saw firsthand how invisible and under-recognised maternal mental health can be. We are changing that — through science, innovation, and precision psychiatry.”

The raise follows a series of national recognitions, including:

  • National Winner, Best Start-Up Solution at the 2025 iAwards

  • Winner, 2025 Women in Technology Future-Focused Business Achiever Award

  • Finalist, Australian Technologies Competition (from 229 entries)

  • Finalist, Pearcey Foundation ICT Entrepreneur of the Year 2025

  • Selection by Brisbane Economic Development Agency for the Global MedTech Accelerator Program and attendance at JP Morgan Healthcare Conference

“We are deeply grateful to our investors, advisors, partners, and team members who have supported this journey,” added Dr. Yates. “The science is ready, the need is urgent, and the momentum is building. At Ketim, we are committed to ensuring maternal mental health is supported with the same rigour, technology, and compassion as any other area of medicine.”

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au

Previous
Previous

Precision Psychiatry Takes the Stage at AGTA2025

Next
Next

Ketim Technologies Founder to Deliver Plenary Address at AGTA2025